CancerGALACTIC-1NCT07372508
Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
A study testing Low dose Chest CT in people with Cancer, run by NHS Greater Glasgow and Clyde at 1 site in United Kingdom.
Trial summary
Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier. Read more about this study
- Who is it for?
- Ages 55 to 74 years
- Conditions the study is for
- Cancer
- What is being tested?
- Low dose Chest CT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 May 2026to 2 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Resident in South Sector NHS GG\&C.
- Capacity to undertake informed consent.
- No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer.
- Aged 55-74 at date of invitation.
- Smoking history: current tobacco smoker or ex-smoker with >20 pack year history and <15 years from quit date.
Who cannot join
- CT thorax scan undertaken in prior 12 months.
- Does not have capacity to give consent (standard criteria for assessing capacity apply).
- Aged <55 or >74 years of age at date of invitation
- Weight exceeds restrictions for scanner (>200kg).
- Unable to lie flat.
- People who are pregnant.
- Active symptoms of possible lung cancer
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Queen Elizabeth University Hospital
Glasgow
Clare Dolan, 0141 314 4328, clare.dolan3@nhs.scot
Geesh Jayasekera
About this study
Official title: GALACTIC 1 - Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier.
Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart and breathing tests within a single clinic visit.
Read more
A Lung Health Check will be offered to people at higher risk of lung cancer, specifically those aged 55-74 with a history of cigarette smoking. This will include a quick and painless LDCT scan, which uses a small amount of radiation to create detailed images of the lungs to detect lung cancer at an early and more treatable stage.
In this "GALACTIC-1" study, the investigators will explore whether structured reporting of the CT scan, combined with additional tests (blood sample, ECG heart trace, and spirometry breathing test), can help identify conditions such as chronic obstructive pulmonary disease (COPD), lung scarring (pulmonary fibrosis), coronary artery disease, heart failure, and early signs of bone fractures (osteoporosis). This enhanced Lung Health Check may improve overall health by identifying and allowing early management of these conditions.
The investigators plan to use the data from the "GALACTIC-1" study to explore AI performance by comparing it to reporting done by doctors. The results will help shape future rollout of lung cancer screening across Scotland, ensuring it is effective, efficient, and beneficial.
The investigators will also have a focus group with patients and interviews with NHS staff to understand their opinions on the screening.
- Conditions
- Cancer
- Being tested
- Low dose Chest CT
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low dose Chest CTDiagnostic test
Low dose Chest CT
| Study group | Role | What they receive |
|---|---|---|
| All patients | Other | All patients Receives: Diagnostic Test: Low dose Chest CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of eligible invited participants who receive all components of the combined low-dose CT (LDCT) screening and AI-assisted cardiorespiratory diagnostic tests within the study active period.
Number of patients successfully screened per protocol within recruitment timelines
Measured: 6 months
Secondary outcomes (13)
Sensitivity of LDCT for detecting confirmed lung cancer (proportion of patients with lung cancer correctly identified as positive).
Measured: Baseline
Specificity of LDCT for detecting confirmed lung cancer (proportion of patients without lung cancer correctly identified as negative).
Measured: Baseline
Lung cancer detection rate
Proportion of participants found to have lung cancer
Measured: Baseline
Stage distribution of detected lung cancers
The proportion detected at Stage I/II vs. Stage III/IV
Measured: Baseline
Detection rate of undiagnosed COPD and/or emphysema in participants.
Measured: Baseline
Detection rate of undiagnosed interstitial lung abnormalities (ILA) and pulmonary fibrosis in participants.
Measured: Baseline
Detection rate of undiagnosed significant coronary artery disease (CAD) in participants
Measured: Baseline
Detection rate of undiagnosed heart failure - radiological, ECG or biomarker (elevated NT-proBNP) indicators requiring further evaluation in participants.
Measured: Baseline
Detection rate of undiagnosed osteoporotic fractures in participants.
Measured: Baseline
Impact of addressable long-term condition case-finding on subsequent investigations, preventative therapy initiation and clinical outcomes.
Accessible health records, investigation requests, prescriptions, hospital admissions and survival at year 1 and year 2 post Galactic-1 clinic will be reviewed to determine the impact the LDCT had on the patient's care.
Measured: Year 1 and Year 2
Performance and potential utility of AI-based radiology co-reporting of lung cancer screening CT scans
Number of radiology reports which agree with the AI report
Measured: Baseline
Acceptability and qualitative evaluation
Participant experience questionnaires will be collected during GALACTIC-1 clinic to provide an overview of experienced acceptability at the time of clinic attendance. Additional focus group or semi-structured interviews will be conducted.
Measured: Baseline
The potential cost-effectiveness of AI-detection of early-stage lung cancer as well as other conditions such as COPD, pulmonary fibrosis, coronary artery disease, heart failure, and osteoporotic fractures
Measured: Year 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2026
- Study start26 May 2026
- Primary completion2 Dec 2026 (estimated)
- Study completion2 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chris Carlin, Principal investigator, NHSGGC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07372508
- Sponsor's protocol ID
- INGN25HS173
- Other IDs
- IRAS: 357735
- Acronym
- GALACTIC-1
- Status last verified
- Jun 2026
- First submitted
- 9 Jan 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GALACTIC 1 - Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
- ClinicalTrials.gov ID
- NCT07372508
- Acronym / sponsor ID
- GALACTIC-1 / INGN25HS173
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- NHS Greater Glasgow and ClydeUniversity, hospital or other
- Study start
- 26 May 2026 (actual)
- Primary completion
- 2 Dec 2026 (estimated)
- Study completion
- 2 Sep 2028 (estimated)
- First posted
- 28 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier.
Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart and breathing tests within a single clinic visit.
A Lung Health Check will be offered to people at higher risk of lung cancer, specifically those aged 55-74 with a history of cigarette smoking. This will include a quick and painless LDCT scan, which uses a small amount of radiation to create detailed images of the lungs to detect lung cancer at an early and more treatable stage.
In this "GALACTIC-1" study, the investigators will explore whether structured reporting of the CT scan, combined with additional tests (blood sample, ECG heart trace, and spirometry breathing test), can help identify conditions such as chronic obstructive pulmonary disease (COPD), lung scarring (pulmonary fibrosis), coronary artery disease, heart failure, and early signs of bone fractures (osteoporosis). This enhanced Lung Health Check may improve overall health by identifying and allowing early management of these conditions.
The investigators plan to use the data from the "GALACTIC-1" study to explore AI performance by comparing it to reporting done by doctors. The results will help shape future rollout of lung cancer screening across Scotland, ensuring it is effective, efficient, and beneficial.
The investigators will also have a focus group with patients and interviews with NHS staff to understand their opinions on the screening.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All patients | Other | Diagnostic Test: Low dose Chest CTAll patients |
Who may qualify
- Ages
- 55 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Resident in South Sector NHS GG\&C.
- Capacity to undertake informed consent.
- No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer.
- Aged 55-74 at date of invitation.
- Smoking history: current tobacco smoker or ex-smoker with >20 pack year history and <15 years from quit date.
Key exclusion criteria (7 listed)
- CT thorax scan undertaken in prior 12 months.
- Does not have capacity to give consent (standard criteria for assessing capacity apply).
- Aged <55 or >74 years of age at date of invitation
- Weight exceeds restrictions for scanner (>200kg).
- Unable to lie flat.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low dose Chest CTLow dose Chest CT | Diagnostic test | All patients |
Primary outcome
Proportion of eligible invited participants who receive all components of the combined low-dose CT (LDCT) screening and AI-assisted cardiorespiratory diagnostic tests within the study active period.
Time frame: 6 months
Number of patients successfully screened per protocol within recruitment timelines
13 secondary outcomes
Sensitivity of LDCT for detecting confirmed lung cancer (proportion of patients with lung cancer correctly identified as positive).
Time frame: Baseline
Specificity of LDCT for detecting confirmed lung cancer (proportion of patients without lung cancer correctly identified as negative).
Time frame: Baseline
Lung cancer detection rate
Time frame: Baseline
Stage distribution of detected lung cancers
Time frame: Baseline
Detection rate of undiagnosed COPD and/or emphysema in participants.
Time frame: Baseline
Detection rate of undiagnosed interstitial lung abnormalities (ILA) and pulmonary fibrosis in participants.
Time frame: Baseline
Detection rate of undiagnosed significant coronary artery disease (CAD) in participants
Time frame: Baseline
Detection rate of undiagnosed heart failure - radiological, ECG or biomarker (elevated NT-proBNP) indicators requiring further evaluation in participants.
Time frame: Baseline
Detection rate of undiagnosed osteoporotic fractures in participants.
Time frame: Baseline
Impact of addressable long-term condition case-finding on subsequent investigations, preventative therapy initiation and clinical outcomes.
Time frame: Year 1 and Year 2
Performance and potential utility of AI-based radiology co-reporting of lung cancer screening CT scans
Time frame: Baseline
Acceptability and qualitative evaluation
Time frame: Baseline
The potential cost-effectiveness of AI-detection of early-stage lung cancer as well as other conditions such as COPD, pulmonary fibrosis, coronary artery disease, heart failure, and osteoporotic fractures
Time frame: Year 2
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingPhase 1/2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ovarian Cancer, Ovarian Neoplasms
RecruitingPhase 1/2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Lymphoma, Non-Hodgkin Lymphoma
RecruitingPhase 3
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chris Carlin principal investigator
NHSGGC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low dose Chest CT in people with Cancer, run by NHS Greater Glasgow and Clyde at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clare Dolan (0141 314 4328, clare.dolan3@nhs.scot), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of eligible invited participants who receive all components of the combined low-dose CT (LDCT) screening and AI-assisted cardiorespiratory diagnostic tests within the study active period. (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.